Clinical Trial Search

Primary: The Time-normalized Number of Hereditary Angioedema Attacks — 0.04; 0.02; 0.12; 0.13 attacks/day — p=< 0.001

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) — 11; 1; 8; 1 Participants

Primary: Time to Beginning of Relief of Symptoms — 68; 122; 258; 62.5 minutes — p=0.001

Primary: Time to Beginning of Relief of Symptoms — 62; 508; 61 minutes — p=0.003

Primary: Mean 7-day Angioedema Activity Score (AAS7) — 2.8; 1.6; 0.69; 0.20 score on a scale

Primary: Number of Confirmed HAE Attacks — 0.519; 0.527; 0.249; 0.852 HAE attacks per week — p=<0.001

Primary: Normalized Number of Angioedema Attacks Per Month in a Treatment Period — 1.2; 0.7 Angioedema attacks per month — p=0.03

Primary: Time-Normalized Number of Attacks (NNA) for Participants During a Treatment Period — 1.611; 3.931 Number of attacks — p=<0.0001

Primary: Presence of Unequivocal Beginning of Relief of the Defining Attack Symptom — 3; 3; 3; 0 participants

Primary: Time to Beginning of Symptom Relief Patient Global Impression of Change (PGI-C) — 1.61; 1.79; 6.72 Time (h) — p=<0.0001

Primary: Safety & Tolerability — 94; 240; 58; 119 Participants

Primary: Change of the 3-symptom Composite Visual Analogue Scale (VAS-3) Score From Pre-treatment to 4 Hours Post-treatment — -14.83; -13.10; -14.37; 1.92 Score on a scale — p=<…

Primary: Time to Conventional Attack Treatment Use Within 12 Hours of Study Drug (Full Analysis Set) — NA; NA Time (h) — p=0.0010

Primary: Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) Score — 13.96; 15.04; 10.54; 18.42 VAS score - millimeters — p=0.0024

Primary: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAE) — 0 Participants